(OAKVILLE, Ontario) July 13, 2022 – Very pleased and proud to announce that our ForYOU Patient Support Program is up and actively supporting Canadian patients. Officially launched and enrolling patients in need as of July 4, with the first dispense of XPOVIO in...
(OAKVILLE, Ontario) June 7, 2022 – FORUS Therapeutics Inc (“FORUS”), is pleased to announce that on May 31, 2022 XPOVIO® (selinexor) was authorized for sale by Health Canada in combination with bortezomib and dexamethasone for the treatment of adult...
(Saint-lgnace-de-Stanbridge, Quebec) May 28th, 2022 – FORUS was a proud sponsor and participant in the Défi Cyclo-Myélome. This is the 10th year of this important event which aims to increase awareness about multiple myeloma and raise funds for the Myeloma Canada...
(TORONTO, Ontario) May 2-3, 2022 – FORUS Therapeutics Inc, a Canadian Life Sciences company specialized in developing and commercializing unique and differentiated oncology focused therapies is proud to be participating and presenting at the 2022 Bloom Burton &...
(OAKVILLE, Ontario) February 22, 2022 – FORUS Therapeutics, a Canadian biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer, today announced it has secured $2.5M CAD in growth capital...
FORUS Therapeutics is delighted to introduce Marie-Josèphe Champagne as the Senior Medical Science Liaison for Québec and Atlantic Canada. Marie-Josèphe has over 18 years of experience in the pharmaceutical industry in commercial and medical affairs roles, primarily...
Recent Comments